Skip to main content

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

Publication ,  Conference
Beer, TM; Armstrong, AJ; Rathkopf, D; Loriot, Y; Sternberg, CN; Higano, CS; Iversen, P; Evans, CP; Kim, C-S; Kimura, G; Miller, K; Saad, F ...
Published in: Eur Urol
February 2017

UNLABELLED: Enzalutamide significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) among men with chemotherapy-naïve metastatic castration-resistant prostate cancer at the prespecified interim analysis of PREVAIL, a phase 3, double-blind, randomized study. We evaluated the longer-term efficacy and safety of enzalutamide up to the prespecified number of deaths in the final analysis, which included an additional 20 mo of follow-up for investigator-assessed rPFS, 9 mo of follow-up for OS, and 4 mo of follow-up for safety. Enzalutamide reduced the risk of radiographic progression or death by 68% (hazard ratio [HR] 0.32, 95% confidence interval [CI] 0.28-0.37; p<0.0001) and the risk of death by 23% (HR 0.77, 95% CI 0.67-0.88; p=0.0002). Median investigator-assessed rPFS was 20.0 mo (95% CI 18.9-22.1) in the enzalutamide arm and 5.4 mo (95% CI 4.1-5.6) in the placebo arm. Median OS was 35.3 mo (95% CI 32.2-not yet reached) in the enzalutamide arm and 31.3 mo (95% CI 28.8-34.2) in the placebo arm. At the time of the OS analysis, 167 patients in the placebo arm had crossed over to receive enzalutamide. The most common adverse events in the enzalutamide arm were fatigue, back pain, constipation, and arthralgia. This final analysis of PREVAIL provides more complete assessment of the clinical benefit of enzalutamide. PREVAIL is registered on ClinicalTrials.gov as NCT01212991. PATIENT SUMMARY: According to data from longer follow-up, enzalutamide continued to provide benefit over placebo in patients with metastatic castration-resistant prostate cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

February 2017

Volume

71

Issue

2

Start / End Page

151 / 154

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Survival Analysis
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Humans
  • Benzamides
  • Antineoplastic Agents
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., … Tombal, B. (2017). Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. In Eur Urol (Vol. 71, pp. 151–154). Switzerland. https://doi.org/10.1016/j.eururo.2016.07.032
Beer, Tomasz M., Andrew J. Armstrong, Dana Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, et al. “Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.” In Eur Urol, 71:151–54, 2017. https://doi.org/10.1016/j.eururo.2016.07.032.
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. In: Eur Urol. 2017. p. 151–4.
Beer, Tomasz M., et al. “Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.Eur Urol, vol. 71, no. 2, 2017, pp. 151–54. Pubmed, doi:10.1016/j.eururo.2016.07.032.
Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim C-S, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017. p. 151–154.

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

February 2017

Volume

71

Issue

2

Start / End Page

151 / 154

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Survival Analysis
  • Prostatic Neoplasms, Castration-Resistant
  • Phenylthiohydantoin
  • Nitriles
  • Male
  • Humans
  • Benzamides
  • Antineoplastic Agents
  • 3202 Clinical sciences